Cocrystal Pharma Announces Abstract Accepted for Oral Presentation at the ISIRV: Options X for the Control of Influenza Confe...
August 21 2019 - 8:05AM
Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the
“Company”), a clinical stage biotechnology company discovering and
developing novel antiviral therapeutics, today announced that
it will present preclinical data of CC-42344 at the ISIRV: Options
X for the Control of Influenza Conference being held August
28-September 1, 2019 in Singapore.
CC-42344 is the Company’s novel, potent, broad
spectrum anti-influenza preclinical lead molecule which targets the
cap-binding PB2 domain, and is active against a panel of seasonal,
pandemic, and Tamiflu-resistant influenza A strains.
The details for the Company’s oral presentation
are as follows:
Topic Category: Clinical Sciences: Therapeutics
AntiviralsAbstract ID: 11025Presenting
Author: Sam Lee, Ph.D. Abstract Title:
Development of a new class of broad spectrum influenza PB2
inhibitorsPresentation Date:
Friday, August 30, 2019Presentation
Time: 10:30 AM - 12:30 PM SGTPresentation
Session: Session 4: Clinical IV
About the International Society for
Influenza and Other Respiratory Virus Diseases (ISIRV)
The ISIRV is an independent and international
scientific professional society promoting the prevention,
detection, treatment, and control of influenza and other
respiratory virus diseases. Options X, the 10th edition of the
Options for the Control of Influenza conference, is ISIRV's premier
event and remains the largest international conference exclusively
dedicated to influenza prevention, control and treatment, including
seasonal flu and pandemic preparedness. Highlights of the meeting
include: new tracks on influenza co-infections with other viral
pathogens and key issues for policy making - a special session to
showcase the latest developments in Chinese-speaking countries -
pre-conference workshops on a wide variety of topics including
technology, mathematical modelling and bioinformatics. For more
information, please visit the conference website.
About Cocrystal Pharma,
Inc.
Cocrystal Pharma, Inc. is a clinical stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication machinery of influenza
viruses, hepatitis C viruses, and noroviruses. Cocrystal employs
unique structure-based technologies and Nobel Prize winning
expertise to create first- and best-in-class antiviral drugs. The
Company is developing CC-31244, an investigational, oral,
broad-spectrum replication inhibitor called a non-nucleoside
inhibitor (NNI). CC-31244 is currently being evaluated in a Phase
2a study for the treatment of hepatitis C as part of a cocktail for
ultra-short therapy of 4 to 6 weeks. Cocrystal recently entered
into an exclusive worldwide license and collaboration agreement
with Merck & Co., Inc. to discover and develop certain
proprietary influenza A/B antiviral agents. CC-42344, the Company’s
molecule for the treatment of influenza A, is currently being
evaluated in preclinical IND-enabling studies. In addition, the
Company has a pipeline of promising early preclinical programs and
continues to identify and develop novel antivirals for the
treatment of norovirus gastroenteritis using the Company’s
proprietary structure-based drug design technology platform. For
further information about Cocrystal, please visit
www.cocrystalpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including the prospects for CC-31244, CC-42344
and the Company’s pipeline of promising preclinical programs. The
words "believe," "may," "estimate," "continue," "anticipate,"
"intend," "should," "plan," "could," "target," "potential," "is
likely," "will," "expect" and similar expressions, as they relate
to us, are intended to identify forward-looking statements. We have
based these forward-looking statements largely on our current
expectations and projections about future events. Some or all of
the events anticipated by these forward-looking statements may not
occur. Important factors that could cause actual results to differ
from those in the forward-looking statements include, but are not
limited to, risks arising from our reliance on continuing
collaboration with Merck under the collaboration agreement, the
availability of products manufactured by third parties, the results
of preclinical and clinical studies, the research organizations’
inability to recruit subjects and complete the studies timely or at
all, including as the result of civil unrest and political
instability in Hong Kong, general risks arising from clinical
trials, receipt of regulatory approvals, our ability to find and
enter into agreements with suitable collaboration partners,
unanticipated litigation and other expenses and factors that affect
the capital markets in general and early stage biotechnology
companies specifically. Further information on our risk factors is
contained in our filings with the SEC, including our Annual Report
on Form 10-K for the year ended December 31, 2018 and the Form 10-Q
for the quarter ended June 30, 2019. Any forward-looking statement
made by us herein speaks only as of the date on which it is made.
Factors or events that could cause our actual results to differ may
emerge from time to time, and it is not possible for us to predict
all of them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
Investor and Media
Contact:Jenene Thomas Communications, LLC(833)
475-8247COCP@jtcir.com
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Sep 2023 to Sep 2024